Pathogen reduction of blood components

Transfusion and Apheresis Science

Volumn 39, Issue 1, 2008, Pages 75-82

  Solheim, Bjarte G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; PSORALEN; RIBOFLAVIN;

ARTICLE; BACTERIAL TRANSMISSION; BIOSAFETY; BLOOD COMPONENT; CHIKUNGUNYA ALPHAVIRUS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EUROPE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MEDICAL TECHNOLOGY; UNITED STATES; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BLOOD CELLS; BLOOD COMPONENT REMOVAL; BLOOD COMPONENT TRANSFUSION; DISINFECTION; HUMANS;

EID: 47349090837     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.05.003     Document Type: Article

References (24)

1. Solheim B.G., Cid J., and Osselaer J.-C. Pathogen reduction technologies. In: Lonzano M., Contreras M., and Blajchman M. (Eds). Global perspectives in transfusion medicine (2006), AABB Press, Bethesda, MD, USA 103-148
2. Epstein J.S., and Vossal J.G. FDA approach to evaluation of pathogen reduction technology. Transfusion 43 (2003) 1347-1350
3. Pelletier J.P.R., Transue S., and Snyder E.L. Pathogen inactivation techniques. Best Practice and Research Clin Haemat 19 (2006) 205-242
4. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apheresis Sci 35 (2006) 83-90
5. Svae T.-E., Neisser-Svae A., Bailey A., Reichl H., Biesert L., Schmidt T., et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apheresis Sci 39 (2008) 59-67
6. Burnouf T., Goubran H.A., Radosevich M., Sayed M.A., Gorgy G., and El-Ekiaby M. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 46 (2006) 2100-2108
7. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion 43 (2003) 1322-1329
8. Depasse F., Sensebe L., Seghatchian J., Andreu G., and Samama M.-M. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerization indices. Transfus Apheresis Sci 33 (2005) 63-69
9. Seghatchian J., and de Sousa G. Pathogen-reduction systems for blood components: the current and future trends. Transfus Apheresis Sci 35 (2006) 189-196
10. Apelseth T.O., Bruserud Ø., Wentzel-Larsen T., Bakken A.M., Bjørsvik S., and Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single donor platelet concentrates during long-term storage. Transfusion 47 (2007) 653-665
11. Apelseth T.O., Hervig T.A., Wentzel-Larsen T., and Bruserud O. Cytokine accumulation in photochemical treated and g-irradiated platelet concentrates during storage. Transfusion 46 (2006) 800-810
12. Osselaer J.C., Doyen C., Messe N., van Hooydonk M., Jacquet M., Sonnet A., et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcome and resources (abstract). Blood 106 (2005) 129a
13. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang 78 Suppl. 2 (2000) 205-210
14. de Alarcon P., Benjamin R., Dugdale M., Kessler C., Shopnick R., Smith P., et al. Fresh frozen plasma prepared with amotosalem HCL (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation deficiencies. Transfusion 45 (2005) 1362-1372
15. Goodrich R.P., Edrich R.A., Li J., and Seghatchian J. The MirasolTM system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apheresis Sci 35 (2006) 5-17
16. AuBuchon J.P., Herschel L., Roger J., Taylor H., Witley P., Li J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005) 1335-1341
17. Li J., Lockerbie O., de Korte D., Rice J., McLean R., and Goodrich P. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 45 (2005) 920-926
18. Perez-Pujol S., Tonda R., Lozano M., Fuste B., Lopez-Vilchez I., Galan A.M., et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 45 (2005) 911-919
19. Benjamin R.J., McCullough J., Mintz P.D., Snyder E., Spotnitz W.D., Rizzo R.J., et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 45 (2005) 1739-1749
20. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
21. Solheim B.G., and Hellstern P. Composition, efficacy, and safety of S/D-treated plasma. Transfusion 43 (2003) 1176-1178
22. Salge-Bartels U., Breitner-Ruddock S., Hunfeld A., Seitz R., and Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma for USA and Europe?. Transfus Med 16 (2006) 266-275
23. Hellstern P. Fresh-frozen plasma, pathogen-reduced single donor plasma or biopharmaceutical plasma?. Transfus Apheresis Sci 39 (2008) 69-74
24. Scully M., Longair I., Flynn M., Berryman J., and Machin S.J. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic pupura. Vox Sang 93 (2007) 153-158